|
|
|
|
|
|
|
|
|
|
|
|
|
20.01.26 - 15:03
|
Peter Melnyk Joins Taiho Oncology as President & Chief Operating Officer (Business Wire)
|
|
|
Mr. Melnyk has more than 30 years of proven experience in oncology commercialization and leadership across pharmaceuticals, medical devices and biotech sectors.
PRINCETON, N.J.--(BUSINESS WIRE)--Taiho Oncology, Inc., a company developing and commercializing novel treatments for hematologic malignancies and solid tumors, announced today Peter Melnyk has joined the company as President & Chief Operating Officer.
Mr. Melnyk comes to Taiho Oncology with more than 30 years of proven experience in oncology commercialization and leadership across pharmaceuticals, medical devices and biotech sectors. Mr. Melnyk joined Taiho Oncology from Alpha Tau Medical, where he was the Chief Commercial Officer and former board member and led the global commercialization efforts for a novel alpha-emitting radiotherapeutic. He was also the CEO of Fortovia Therapeutics and drove the transformation and portfolio expansion in oncology supportive care. In addition, Mr. Melnyk was the Chief Commercial Officer at Novocure, where he b...
|
|
|
|
|
12.01.26 - 13:06
|
Novocure Announces Preliminary Full Year and Fourth Quarter 2025 Performance and Provides Company Update (Business Wire)
|
|
|
Preliminary full year 2025 net revenues of $655 million and fourth quarter net revenues of $174 million
Novocure to present at the 44th Annual J.P. Morgan Healthcare Conference at 9:45 a.m. PST on Wednesday, January 14, 2026BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) today reported preliminary unaudited financial and operational results for the quarter and full year ended December 31, 2025. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields).
“Novocure exits 2025 having achieved record annual revenue, providing the financial strength to execute on the exciting growth opportunities we have in 2026,” said Frank Leonard, CEO, Novocure. “We have built the team and capabilities to support multiple product launches in the coming year while ensuring the company is on a clear path to profitability.”
Financial updates for the year and fourth ...
|
|
|
|
|
|
|
|
|
|
|
|
|
01.12.25 - 13:06
|
Novocure Appoints Company President Frank Leonard as Chief Executive Officer (Business Wire)
|
|
|
BAAR, Switzerland--(BUSINESS WIRE)--$NVCR--Novocure (NASDAQ: NVCR) today announced the appointment of Frank Leonard as Chief Executive Officer (CEO), effective immediately. Mr. Leonard previously served as President of Novocure and succeeds Ashley Cordova who has resigned from the company.
“During his more than 15-year career at Novocure, Frank has led many of our global business operations developing deep expertise in delivering our unique, device-based cancer therapy to patients to extend their survivals. Frank has been instrumental in creating Novocure's culture and guiding the organization at critical points, including preparing the company for its first commercial launch and establishing the business functions that continue to drive our growth,” said William Doyle, Executive Chairman, Novocure. “Frank embodies Novocure's core values and has an unwavering commitment to our patient-forward mission. He is the ideal person to lead our organization through the exciting, transformative milestones a...
|
|
|
|
|
|
|
|
|
|
|
|
|
30.10.25 - 14:18
|
Novocure Posts Wider Loss In Q3 (AFX)
|
|
|
WASHINGTON (dpa-AFX) - Novocure (NVCR) reported a third quarter net loss of $37.3 million compared to a loss of $30.6 million, prior year. Net loss per ordinary share was $0.33 compared to a loss ......
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
